[ad_1]
The University of Oxford said on Tuesday it had paused a small UK trial testing the COVID-19 vaccine it developed with AstraZeneca in children and teenagers, as it waits for more data on rare blood clotting issues in adults who received the shot.
The trial disruption is the latest blow to the vaccine, once hailed as a milestone in the fight against the pandemic, after several countries restricted its use in light of reports of medical issues after inoculations.
For more coronavirus news, visit our dedicated page.
There were no safety concerns in the pediatric trial, Oxford University said, adding that it would await guidance from the UK drugs watchdog before giving any further vaccinations.
The university said in February it planned to enroll 300 volunteers aged 6-17 years, based in the United Kingdom, as part of this study.
The European Medicines Agency (EMA) is currently reviewing reports of an extremely rare brain blood clot known as cerebral venous sinus thrombosis (CVST) after the AstraZeneca shots, and is expected to announce its findings on Wednesday or Thursday.
For the latest headlines, follow our Google News channel online or via the app.
A senior EMA official has said there is a clear association between the vaccine and CVST, though the direct cause of the clots is still unknown.
The World Health Organization, which is closely studying the latest data on AstraZeneca’s vaccine alongside other regulators, said on Tuesday it expects to there will be no reason to change its assessment that the shot’s benefits outweigh any risks.
Spats with governments across Europe about production, supplies, possible side effects and the vaccine’s merits have dogged the Anglo-Swedish drugmaker for months.
Anthony Fauci, the top US infectious disease doctor, told Reuters last week the United States may not need AstraZeneca’s vaccine, even if it wins regulatory approval.
Read more:
WHO recommends continued use of AstraZeneca vaccine, says benefits outweigh risks
Fauci says US may not need AstraZeneca COVID-19 vaccine
[ad_2]
Source link
